530125 On Other Exchanges
Symbol
Exchange
530125 is not on other exchanges.

samrat pharmachem ltd (530125) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SAMRAT PHARMACHEM LTD (530125)

Related News

No related news articles were found.

samrat pharmachem ltd (530125) Related Businessweek News

No Related Businessweek News Found

samrat pharmachem ltd (530125) Details

Samrat Pharmachem Limited produces and sells pharmaceutical chemicals in India. The company primarily sells iodine and bromine salts. Its products include calcium iodate monohydrate, copper iodide, hydriodic acid, iodine, iodine monochloride, iodoethane, iodomethane, potassium bromide, potassium iodate, potassium iodide, potassium metaperiodate, sodium iodate, sodium iodide, sodium metaperiodate, and trimethyl sulfoxoniumiodide. The company’s finished products are primarily used in various industries, including pharmaceuticals, chemicals, food, fertilizer, salt, etc. Samrat Pharmachem Limited also exports its products. The company was incorporated in 1992 and is based in Mumbai, India.

29 Employees
Last Reported Date: 05/30/16
Founded in 1992

samrat pharmachem ltd (530125) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: 1.5M
Executive Director of Finance, Compliance Off...
Total Annual Compensation: 1.4M
Executive Director
Total Annual Compensation: 210.0K
Compensation as of Fiscal Year 2016.
samrat pharmachem ltd
Samrat Pharmachem Limited Reports Unaudited Standalone Earnings Results for Second Quarter and Six Months Ended September 30, 2016

Samrat Pharmachem Limited reported unaudited standalone earnings results for second quarter and six months ended September 30, 2016. For the quarter, the company reported net sales/income from operations of INR 186.497 million, profit from operations before other income and finance costs and exceptional items of INR 8.022 million, profit from ordinary activities before tax of INR 5.507 million, net profit of INR 4.173 million or INR 1.35 per basic and diluted share, compared to the net sales/income from operations of INR 127.74 million, profit from operations before other income and finance costs and exceptional items of INR 1.238 million, profit from ordinary activities before tax of INR 0.485 million, net profit of INR 0.434 million or INR 0.14 per basic and diluted share, for the same quarter a year ago. For the year to date, the company reported net sales/income from operations of INR 399.245 million, profit from operations before other income and finance costs and exceptional items of INR 13.158 million, profit from ordinary activities before tax of INR 9.427 million, net profit of INR 6.663 million or INR 2.16 per basic and diluted share, compared to the net sales/income from operations of INR 253.393 million, profit from operations before other income and finance costs and exceptional items of INR 2.739 million, profit from ordinary activities before tax of INR 1.683 million, net profit of INR 1.138 million or INR 0.37 per basic and diluted share, for the same period a year ago.

Samrat Pharmachem Limited to Report Q2, 2017 Results on Nov 14, 2016

Samrat Pharmachem Limited announced that they will report Q2, 2017 results on Nov 14, 2016

Samrat Pharmachem Limited, Board Meeting, Nov 14, 2016

Samrat Pharmachem Limited, Board Meeting, Nov 14, 2016. Agenda: To consider the un-audited financial results of the company for the second quarter ended September 30, 2016.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

530125 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 530125.
View Industry Companies
 

Industry Analysis

530125

Industry Average

Valuation 530125 Industry Range
Price/Earnings 15.2x
Price/Sales 0.2x
Price/Book 0.9x
Price/Cash Flow 9.9x
TEV/Sales 0.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SAMRAT PHARMACHEM LTD, please visit www.samratpharmachem.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.